Induction of SARS-CoV-2 Spike Glycoprotein Antibodies in Saliva and Plasma in Response to a COVID-19 Infection, Systemic COVID-19 Vaccination, and the Combination of COVID-19 and Vaccination
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 500
- 主要终点
- Titer of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma
研究概览
简要总结
The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infected, COVID-19 Convalescents, Persons Vaccinated With Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1 nCov-19 AZD1222 Vaccines, and Convalescent COVID-19 Patients That Have Subsequently Been Vaccinated. A Potential Difference in the Immunoglobulin Concentrations of the Pfizer-BioNTech BNT162b2 Vaccine, Moderna mRNA-1273 vaccine and the AstraZeneca ChAdOx1-S Vaccine Will be Uncovered. This Knowledge About the Mucosal Immunity Will be Important for Further Designing of Vaccine Strategies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Written informed consent
- •Both Hospital staff as well as non-health care workers will be invited to participate
排除标准
- •Individuals not fulfilling the inclusion criteria or declining blood or saliva collection.
- •Exclusion criteria are neck breathers (tracheostomy/laryngectomy patients) or other nasopharyngeal or oropharyngeal anomalies that do not allow for sampling using Salivette.
结局指标
主要结局
Titer of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma
时间窗: Between 21 and 200 days after infection/vaccination
Detection of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma in participants who have been infected with COVID-19, vaccinated with Pfizer-BioNTech/Moderna mRNA-1273/AstraZeneca or infected and vaccinated
次要结局
- Titer of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma(Between 21 and 200 days after vaccination)
研究者
Lenanrt Friis-Hansen
Department of Clinical Biochemistry MD, DMSc, Principal Investigator
University Hospital Bispebjerg and Frederiksberg